Skip to main content
Top
Published in: Current Rheumatology Reports 5/2014

01-05-2014 | VASCULITIS (LR ESPINOZA, SECTION EDITOR)

Non-Infectious Cryoglobulinemia Vasculitis (CryoVas): Update on Clinical and Therapeutic Approach

Authors: Rodolfo Perez-Alamino, Luis R. Espinoza

Published in: Current Rheumatology Reports | Issue 5/2014

Login to get access

Abstract

CryoVas is a small vessel vasculitis associated with the presence of circulating cryoglobulins. In the absence of HCV infection, several disorders have been identified in association of CryoVas. Although evidence is limited, a few studies have recently described the clinical presentation, prognosis, and therapeutic management of non-infectious CryoVas. Patients with type I CryoVas, especially associated with hematologic malignancies, have shown a worse clinical presentation. Recent studies have also identified prognostic factors in mixed CryoVas. Therapeutic management in non-infectious CryoVas remains to be defined. Overall, treatment options should be individualized based on severity of involvement. In this setting, new data have emerged regarding the role of biologic therapy in non-infectious CryoVas. Off-label use of rituximab should be highlighted, based on the assessment of benefits and risks, especially infections.
Literature
1.•
go back to reference Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25:10–8. Comprehensive report with a complete literature review on clinical and laboratory manifestations and new therapeutic approaches of cryoglobulinemia vasculitis. PubMedCrossRef Terrier B, Cacoub P. Cryoglobulinemia vasculitis: an update. Curr Opin Rheumatol. 2013;25:10–8. Comprehensive report with a complete literature review on clinical and laboratory manifestations and new therapeutic approaches of cryoglobulinemia vasculitis. PubMedCrossRef
2.
go back to reference Lerner AB, Watson CJ. Studies of cryoglobulins I: unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin). Am J Med Sci. 1947;214:410–5.PubMedCrossRef Lerner AB, Watson CJ. Studies of cryoglobulins I: unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin). Am J Med Sci. 1947;214:410–5.PubMedCrossRef
3.
go back to reference Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med. 1974;57:775–88.PubMedCrossRef Brouet JC, Clauvel JP, Danon F, et al. Biologic and clinical significance of cryoglobulins: a report of 86 cases. Am J Med. 1974;57:775–88.PubMedCrossRef
4.
go back to reference Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80:252–62.CrossRef Trejo O, Ramos-Casals M, Garcia-Carrasco M, et al. Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center. Medicine (Baltimore). 2001;80:252–62.CrossRef
5.
go back to reference Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166:2101–8.PubMedCrossRef Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with nonhepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166:2101–8.PubMedCrossRef
6.••
go back to reference Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012;379:348–60. An outstanding review with a complete description of pathophysiology, clinical manifestations, diagnosis, and treatment approaches of cryoglobulinemia vasculitis. PubMedCrossRef Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet. 2012;379:348–60. An outstanding review with a complete description of pathophysiology, clinical manifestations, diagnosis, and treatment approaches of cryoglobulinemia vasculitis. PubMedCrossRef
7.
go back to reference Della Rossa A, Tavoni A, Bombardieri S. Hyperviscosity syndrome in cryoglobulinaemia: clinical aspects and therapeutic considerations. Semin Thromb Hemost. 2003;29:473–7.PubMedCrossRef Della Rossa A, Tavoni A, Bombardieri S. Hyperviscosity syndrome in cryoglobulinaemia: clinical aspects and therapeutic considerations. Semin Thromb Hemost. 2003;29:473–7.PubMedCrossRef
8.
go back to reference Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med. 1980;69:287–308.PubMedCrossRef Gorevic PD, Kassab HJ, Levo Y, et al. Mixed cryoglobulinemia: clinical aspects and long-term follow-up of 40 patients. Am J Med. 1980;69:287–308.PubMedCrossRef
9.
go back to reference Tzioufas A, Boumba D, Skopouli F, et al. Mixed monoclonal cryoglobulinaemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren’s syndrome. Arthritis Rheum. 1996;39:767–72.PubMedCrossRef Tzioufas A, Boumba D, Skopouli F, et al. Mixed monoclonal cryoglobulinaemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjogren’s syndrome. Arthritis Rheum. 1996;39:767–72.PubMedCrossRef
10.
go back to reference Brito-Zerón P, Ramos-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46:1359–62.CrossRef Brito-Zerón P, Ramos-Casals M, Bove A, et al. Predicting adverse outcomes in primary Sjögren’s syndrome: identification of prognostic factors. Rheumatology (Oxford). 2007;46:1359–62.CrossRef
11.
go back to reference García-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinaemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum. 2001;30:366–73.PubMedCrossRef García-Carrasco M, Ramos-Casals M, Cervera R, et al. Cryoglobulinaemia in systemic lupus erythematosus: prevalence and clinical characteristics in a series of 122 patients. Semin Arthritis Rheum. 2001;30:366–73.PubMedCrossRef
12.
go back to reference Morra E. Cryoglobulinemia. ASH Education Book. Hematol Am Soc Hematol Educ Program. 2005;1:368–72.CrossRef Morra E. Cryoglobulinemia. ASH Education Book. Hematol Am Soc Hematol Educ Program. 2005;1:368–72.CrossRef
13.
go back to reference Trejo O, Ramos-Casals M, López-Guillermo A, et al. Hematologic malignancies in patients with cryoglobulinaemia: association with autoimmune and chronic viral diseases. Semin Arthritis Rheum. 2003;33:19–28.PubMedCrossRef Trejo O, Ramos-Casals M, López-Guillermo A, et al. Hematologic malignancies in patients with cryoglobulinaemia: association with autoimmune and chronic viral diseases. Semin Arthritis Rheum. 2003;33:19–28.PubMedCrossRef
14.••
go back to reference Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119:5996–6004. This is the largest series so far published on non-infectious mixed CryoVas analyzing the safety and efficacy of different treatment approaches. Rituximab and corticosteroids showed greater efficacy although were associated with severe infections. PubMedCrossRef Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood. 2012;119:5996–6004. This is the largest series so far published on non-infectious mixed CryoVas analyzing the safety and efficacy of different treatment approaches. Rituximab and corticosteroids showed greater efficacy although were associated with severe infections. PubMedCrossRef
15.
go back to reference Damoiseaux J and Cohen Tervaert JW. Diagnostics and treatment of cryoglobulinemia: it takes two to tango. Clin Rev Allerg Immunol 2013. Damoiseaux J and Cohen Tervaert JW. Diagnostics and treatment of cryoglobulinemia: it takes two to tango. Clin Rev Allerg Immunol 2013.
16.••
go back to reference Terrier B, Karras A, Kahn J, et al. The spectrum of type I cryoglobulinemia vasculitis. Medicine. 2013;92:61–8. This study describes the presentation, prognosis, and therapeutic management of the largest series of type I CryoVas patients. Severe cutaneous manifestations and high serum cryoglobulin levels characterized type I CryoVas, although the frequency of glomerulonephritis was lower than expected. PubMedCrossRef Terrier B, Karras A, Kahn J, et al. The spectrum of type I cryoglobulinemia vasculitis. Medicine. 2013;92:61–8. This study describes the presentation, prognosis, and therapeutic management of the largest series of type I CryoVas patients. Severe cutaneous manifestations and high serum cryoglobulin levels characterized type I CryoVas, although the frequency of glomerulonephritis was lower than expected. PubMedCrossRef
17.•
go back to reference Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis. 2013;72:374–80. This study included 242 patients with non-infectious mixed CryoVas. Causes of death and prognostic factors of survival were assessed and a prognostic score was determined to predict survival at 5 years. Main prognostic factors were age older than 65 years, pulmonary and gastrointestinal involvement, and renal failure. PubMedCrossRef Terrier B, Carrat F, Krastinova E, et al. Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis: data from 242 cases included in the CryoVas survey. Ann Rheum Dis. 2013;72:374–80. This study included 242 patients with non-infectious mixed CryoVas. Causes of death and prognostic factors of survival were assessed and a prognostic score was determined to predict survival at 5 years. Main prognostic factors were age older than 65 years, pulmonary and gastrointestinal involvement, and renal failure. PubMedCrossRef
18.
go back to reference Terrier B, Semoun O, Saadoun D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63:1748–57.PubMedCrossRef Terrier B, Semoun O, Saadoun D, et al. Prognostic factors in patients with hepatitis C virus infection and systemic vasculitis. Arthritis Rheum. 2011;63:1748–57.PubMedCrossRef
19.
go back to reference Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62:1787–95.CrossRef Terrier B, Launay D, Kaplanski G, et al. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry. Arthritis Care Res (Hoboken). 2010;62:1787–95.CrossRef
20.
go back to reference Payet J, Livartowski J, Kavian N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013;54(4):767–77.PubMedCrossRef Payet J, Livartowski J, Kavian N, et al. Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature. Leuk Lymphoma. 2013;54(4):767–77.PubMedCrossRef
21.
go back to reference Nehme-Schuster H, Korganow A, Pasquali J, et al. Rituximab inefficiency during type I cryoglobulinemia. Rheumatology (Oxford). 2005;44:410–1.CrossRef Nehme-Schuster H, Korganow A, Pasquali J, et al. Rituximab inefficiency during type I cryoglobulinemia. Rheumatology (Oxford). 2005;44:410–1.CrossRef
22.
go back to reference Pandrangi S, Singh A, Wheeler D, et al. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Clin Pract Nephrol. 2008;4:393–7.PubMedCrossRef Pandrangi S, Singh A, Wheeler D, et al. Rituximab treatment for a patient with type I cryoglobulinemic glomerulonephritis. Nat Clin Pract Nephrol. 2008;4:393–7.PubMedCrossRef
23.
go back to reference Calabrese C, Faiman B, Martin D, et al. Type 1 cryoglobulinemia: response to thalidomide and lenalidomide. J Clin Rheumatol. 2011;17:145–7.PubMedCrossRef Calabrese C, Faiman B, Martin D, et al. Type 1 cryoglobulinemia: response to thalidomide and lenalidomide. J Clin Rheumatol. 2011;17:145–7.PubMedCrossRef
24.
go back to reference Lin R, Curran J, Zimmerman T, et al. Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. J Clin Rheumatol. 2010;16:90–1.PubMedCentralPubMedCrossRef Lin R, Curran J, Zimmerman T, et al. Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. J Clin Rheumatol. 2010;16:90–1.PubMedCentralPubMedCrossRef
Metadata
Title
Non-Infectious Cryoglobulinemia Vasculitis (CryoVas): Update on Clinical and Therapeutic Approach
Authors
Rodolfo Perez-Alamino
Luis R. Espinoza
Publication date
01-05-2014
Publisher
Springer US
Published in
Current Rheumatology Reports / Issue 5/2014
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI
https://doi.org/10.1007/s11926-014-0420-0

Other articles of this Issue 5/2014

Current Rheumatology Reports 5/2014 Go to the issue

PSORIATIC ARTHRITIS (O FITZGERALD AND P HELLIWELL, SECTION EDITORS)

Patient Involvement in Outcome Measures for Psoriatic Arthritis

RHEUMATOID ARTHRITIS (LW MORELAND, SECTION EDITOR)

Preclinical Rheumatoid Arthritis (Autoantibodies): An Updated Review

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.